---
title: "Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer"
slug: "tailoring-adjuvant-endocrine-therapy-for-premenopausal-breast-cancer"
date: "2023-10-25"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[Suppression of Ovarian Function Trial]]

# Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

- premenopausal estrogen-receptor-positive breast cancer
- Extending the duration of tamoxifen treatment to 10 years further improves outcomes
- ä»–æ”¶äº†äº”åƒä¸ƒç™¾å¤šå€‹ç—…äººï¼ŒæŠŠç—…äººåˆ†åœ¨å…©çµ„ä¸­ï¼šä¸€çµ„èµ°SOFTä¸€çµ„èµ°TEXT
- ä¸»è¦å°±æ˜¯æ¯”è¼ƒTamoxifen alone / + OFS / + [[Exemestane]]

![Figure: height:450px](https://i.imgur.com/7poJ2Zr.png)

## Disease-free Survival among All Patients and According to HER2 and Chemotherapy Status in SOFT

![Figure: height:450px](https://i.imgur.com/GczwIF9.png)

- å¾åœ–è¡¨çœ‹èµ·ä¾†ï¼Œåœ¨ç”¨Tamoxifen çš„ â†’ ç—…äººä¸­
  - HER2 negative, Chemotherapy æœ‰æˆ–æ²’åšï¼Œéƒ½æœ‰è·¨éä¸€ï¼Œ âˆ´ æ‰€ä»¥å¯èƒ½ âœ– ä¸ä¸€å®šæœ‰å¹«åŠ©
- è€Œç”¨äº†Exemestane + OFS æ¯”è¼ƒ TAM aloneçš„ â†’ ç—…äººä¸­
  - åè€Œæ˜¯HER2 positive çš„ â†’ å¹«åŠ©æ¯”è¼ƒæœ‰é™
- ä½†ä¸€èµ·çœ‹ï¼Œä»¥HRçš„ â†’ æ•¸å€¼çœ‹èµ·ä¾†ï¼ŒExemestane çœ‹èµ·ä¾†æ¯”è¼ƒæœ‰æ•ˆ
